A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

Clinical Trial ID NCT02046694

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02046694

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 11.30
2 Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012 2.82
3 Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007 2.77
4 The purine path to chemotherapy. Science 1989 2.47
5 Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 1990 1.91
6 Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005 1.79
7 Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010 1.09
8 Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983 1.00
9 Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008 0.96
10 Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998 0.91
11 Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008 0.77
12 Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer 2013 0.77
Next 100